Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 2, 2011, Pages 280-288

  Peng, Chunjie ^a   Zhang, Xiaolei ^a   Yu, Hongli ^a   Wu, Donglai ^b   Zheng, Jianhua ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Chemoresistance; Immunohistochemistry; Ovarian cancer; Prognosis; Wnt5a

Indexed keywords

EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MICRORNA; OXALIPLATIN; PACLITAXEL; WNT5A PROTEIN;

ADULT; ARTICLE; ASSAY; CANCER CELL; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHEMORESISTANCE; CHEMOSENSITIVITY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVARY CANCER; OVARY TUMOR; OVERALL SURVIVAL; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VECTOR CONTROL; WESTERN BLOTTING;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; OVARY; PROTO-ONCOGENE PROTEINS; WNT PROTEINS;

EID: 79956116022     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31820aaadb     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007 CA Cancer J Clin. 2007;57:43-66. (Pubitemid 46148091)
2. Yao HH, Matzuk MM, Jorgez CJ, et al. Follistatin operates downstream of Wnt4 in mammalian ovary organogenesis. Dev Dyn. 2004;230:210-215. (Pubitemid 38669583)
3. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesisVa look outside the nucleus. Science. 2000;287:1606-1609. (Pubitemid 30127755)
4. Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of α-catenin-independent Wnt signaling. Dev Cell. 2003;5:367-377. (Pubitemid 37107667)
5. Ford CE, Ekstrom EJ, Andersson T. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. Proc Natl Acad Sci U S A. 2009;106:3919-3924.
6. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 2002;1:279-288. (Pubitemid 41039152)
7. Dejmek J, Dejmek A, Safholm A, et al. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res. 2005;65:9142-9146. (Pubitemid 41507974)
8. Yu JM, Jun ES, Jung JS, et al. Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer Lett. 2007;257:172-181. (Pubitemid 47538822)
9. Matei D, Graeber TG, Baldwin RL, et al. Gene expression in epithelial ovarian carcinoma. Oncogene. 2002;21:6289-6298.
10. Badiglian Filho L, Oshima CT, De Oliveira Lima F, et al. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep. 2009;21:313-320.
11. Varma RR, Hector SM, Clark K, et al. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10 Oncol Rep. 2005;14:925-932.
12. Grandjean F, Bremaud L, Verdier M, et al. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines. Anticancer Drugs. 2001;12:247-258. (Pubitemid 32269921)
13. de Anta JM, Perez-Castro AJ, Freire R, et al. The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance. Anticancer Drugs. 2006;17:1171-1177. (Pubitemid 44673397)
14. Iozzo RV, Eichstetter I, Danielson KG. Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res. 1995;55:3495-3499.
15. Kremenevskaja N, von Wasielewski R, Rao AS, et al. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene. 2005;24:2144-2154. (Pubitemid 40516581)
16. Jonsson M, Dejmek J, Bendahl PO, et al. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res. 2002;62:409-416. (Pubitemid 34106413)
17. Bui TD, Zhang L, Rees MC, et al. Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma. Br J Cancer. 1997;75:1131-1136. (Pubitemid 27140023)
18. Kuhl M, Sheldahl LC, Malbon CC, et al. Ca(2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J Biol Chem. 2000;275:12701-12711. (Pubitemid 30241421)
19. Dissanayake SK, Wade M, Johnson CE, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 2007;282:17259-17271. (Pubitemid 47093253)
20. Liang H, Coles AH, Zhu Z, et al. Noncanonical Wnt signaling promotes apoptosis in thymocyte development. J Exp Med. 2007;204:3077-3084.
21. Weichert W, Gekeler V, Denkert C, et al. Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int J Oncol. 2003;23:633-639.
22. Righetti SC, Perego P, Carenini N, et al. Molecular alterations of cells resistant to platinum drugs: role of PKCα. Biochim Biophys Acta. 2006;1763:93-100. (Pubitemid 43208736)
23. Isonishi S, Ohkawa K, Tanaka T, et al. Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Br J Cancer. 2000;82:34-38. (Pubitemid 30008955)